Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 1
2003 1
2008 3
2009 3
2012 2
2013 2
2014 2
2015 3
2016 1
2017 2
2018 1
2019 1
2021 2
2022 2
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial.
Lee W, Kim M. Lee W, et al. Medicine (Baltimore). 2024 Jun 14;103(24):e38067. doi: 10.1097/MD.0000000000038067. Medicine (Baltimore). 2024. PMID: 38875437 Free PMC article. Clinical Trial.
BACKGROUND: Choline alfoscerate (alpha-glycerylphosphorylcholine) is a phospholipid that includes choline, which increases the release of acetylcholine. The ASCOMALVA trial, a combination of donepezil and choline alfoscerate, slowed cogni …
BACKGROUND: Choline alfoscerate (alpha-glycerylphosphorylcholine) is a phospholipid that includes choline, which …
Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers.
Min MH, Park JH, Hur JH, Shin HC, Cho Y, Kim DD. Min MH, et al. Drug Des Devel Ther. 2019 Apr 5;13:1049-1058. doi: 10.2147/DDDT.S193424. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31040642 Free PMC article. Clinical Trial.
Subjects were orally treated with 1,200 mg of test or reference choline alfoscerate (400 mg three doses) formulation. Blood samples were collected up to 12 hours the day before dosing to correct the baseline level of choline and 12 hours after dosing to obtai …
Subjects were orally treated with 1,200 mg of test or reference choline alfoscerate (400 mg three doses) formulation. Blood sa …
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Sagaro GG, Traini E, Amenta F. Sagaro GG, et al. J Alzheimers Dis. 2023;92(1):59-70. doi: 10.3233/JAD-221189. J Alzheimers Dis. 2023. PMID: 36683513 Free PMC article.
BACKGROUND: Choline alphoscerate (alpha glyceryl phosphorylcholine, alpha-GPC) is a choline-containing phospholipid used as a medicine or nutraceutical to improve cognitive function impairment occurring in neurological conditions including adult-onset dementia disor …
BACKGROUND: Choline alphoscerate (alpha glyceryl phosphorylcholine, alpha-GPC) is a choline-containing phospholipid used as a …
[Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study].
Ponomareva EV, Androsova LV, Krinsky SA, Gavrilova SI. Ponomareva EV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4. Vyp. 2):92-99. doi: 10.17116/jnevro202412404292. Zh Nevrol Psikhiatr Im S S Korsakova. 2024. PMID: 38696157 Clinical Trial. Russian.
OBJECTIVE: To study the efficacy and safety of the use of annual course therapy of choline alfoscerate (CA) as a drug potentially capable of slowing or preventing the transition of amnesic type mild cognitive impairment (aMCI) into clinically pronounced dementia in …
OBJECTIVE: To study the efficacy and safety of the use of annual course therapy of choline alfoscerate (CA) as a drug potentia …
Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M. De Jesus Moreno Moreno M. Clin Ther. 2003 Jan;25(1):178-93. doi: 10.1016/s0149-2918(03)90023-3. Clin Ther. 2003. PMID: 12637119 Clinical Trial.
Despite encouraging early results, well-controlled clinical trials did not confirm a clinical utility of cholinergic precursors such as choline and lecithin (phosphatidylcholine) in AD. OBJECTIVE: This study assessed the efficacy and tolerability of the cholinergic precurs …
Despite encouraging early results, well-controlled clinical trials did not confirm a clinical utility of cholinergic precursors such as c
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Salvadori E, Poggesi A, Donnini I, Rinnoci V, Chiti G, Squitieri M, Tudisco L, Fierini F, Melone A, Pescini F, Pantoni L. Salvadori E, et al. Drugs Aging. 2021 Jun;38(6):481-491. doi: 10.1007/s40266-021-00852-8. Epub 2021 Apr 15. Drugs Aging. 2021. PMID: 33855653 Free PMC article. Clinical Trial.
BACKGROUND: No approved treatment is available for patients with vascular cognitive impairment (VCI) due to cerebral small vessel disease (SVD). OBJECTIVE: The CONIVaD (Choline Alphoscerate and Nimodipine in Vascular Dementia) study aimed to investigate the feasibility, ef …
BACKGROUND: No approved treatment is available for patients with vascular cognitive impairment (VCI) due to cerebral small vessel disease (S …
Variation of betaine, N,N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period.
McEntyre CJ, Lever M, Chambers ST, George PM, Slow S, Elmslie JL, Florkowski CM, Lunt H, Krebs JD. McEntyre CJ, et al. Ann Clin Biochem. 2015 May;52(Pt 3):352-60. doi: 10.1177/0004563214545346. Epub 2014 Jul 10. Ann Clin Biochem. 2015. PMID: 25013088 Clinical Trial.
We measured the concentrations of the osmolytes: betaine, glycerophosphorylcholine (GPC) and taurine, as well as TMAO, and the one-carbon metabolites, N,N-dimethylglycine (DMG) and free choline. Samples were measured using tandem mass spectrometry (LC-MS/MS). ...CONCLUSION …
We measured the concentrations of the osmolytes: betaine, glycerophosphorylcholine (GPC) and taurine, as well as TMAO, and the one-carbon me …
A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers.
Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. Gatti G, et al. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):331-5. Int J Clin Pharmacol Ther Toxicol. 1992. PMID: 1428296 Clinical Trial.
L-alpha-glycerylphosphorylcholine (alpha-GPC) is a recently developed cognitive enhancer whose mode of action is considered to involve the release of free choline, which is then utilized for acetylcholine and phosphatidylcholine biosynthesis in the brain. ...In the …
L-alpha-glycerylphosphorylcholine (alpha-GPC) is a recently developed cognitive enhancer whose mode of action is considered to involv …
33 results